Drug Trial Radar · NCT01211522
The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study
Last checked: Nov 20, 2026Latest source record: Nov 18, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
566
Actual
Start
Dec 14, 2011
Primary completion
Aug 28, 2017
Study completion Jul 19, 2018
Sponsor
- Lead sponsor
- Vanderbilt University Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 29, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The long-term objective of the MIND-USA (Modifying the Impact of ICU-Induced Neurological Dysfunction-USA) Study is to define the role of antipsychotics in the management of delirium in vulnerable critically ill patients. We and others have shown that delirium is an independent predictor of more death, longer stay, higher cost, and long-term cognitive impairment often commensurate with moderate dementia. The rapidly expanding aging ICU population is especially vulnerable to develop delirium, with 7 of 10 medical and surgical ICU patients developing this organ dysfunction. Antipsychotics are the first-line pharmacological agents recommended to treat delirium, and over the past 30 years they gained widespread use in hospitalized patients globally prior to adequate testing of efficacy and safety for this indication. Haloperidol, the most commonly chosen antipsychotic, is used by over 80% of ICU doctors for delirium, while atypical antipsychotics are prescribed by 40%. Antipsychotics safety concerns include lethal cardiac arrhythmias, extrapyramidal symptoms, and the highly publicized increased mortality associated with their use in non-ICU geriatric populations. The overarching hypothesis is that administration of typical and atypical antipsychotics-haloperidol and ziprasidone, in this case-to critically ill patients with delirium will improve short- and long-term clinical outcomes, including days alive without acute brain dysfunction (referred to as delirium/coma-free days or DCFDs) over a 14-day period; 30-day, 90-day, and 1-year survival; ICU length of stay; incidence, severity, and/or duration of long-term neuropsychological dysfunction; and quality of life at 90-day and 1-year. To test these hypotheses, the MIND-USA Study will be a multi-center, double-blind, randomized, placebo-controlled investigation in 561 critically ill, delirious medical/surgical ICU patients who are (a) on mechanical ventilation or non-invasive positive pressure ventilation or (b) in shock on vasopressors. In each group (haloperidol, ziprasidone, and placebo), 187 patients will be enrolled and treated until delirium has resolved for 48 hours or to 14 days (whichever occurs first) and followed for 1 year.
Conditions
- Delirium
- Impaired Cognition
- Long Term Psychologic Disorders
Interventions
HaloperidolDrug
Haloperidol, up to 10mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 5mg/mL. Patient will only receive IV while in the ICU.
ZiprasidoneDrug
Ziprasidone, up to 20mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 10mg/mL. Patient will only receive IV while in the ICU.
PlaceboDrug
Placebo, up to 10mL q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes. Patient will only receive IV while in the ICU.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Delirium/Coma-free Days (DCFDs)Time frame: 14 days
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Denver Health/University of Colorado Health Sciences Center
Denver, Colorado
Yale University Medical Center
New Haven, Connecticut
Indiana University
Indianapolis, Indiana
University of Iowa
Iowa City, Iowa
University of Maryland Medical Center
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts
University of Michigan Health System
Ann Arbor, Michigan
Albert Einstein Medical College-Montefiore Medical Center
The Bronx, New York
University of North Carolina - Chapel Hill
Chapel Hill, North Carolina
Moses Cone Health System
Greensboro, North Carolina
The Ohio State Medical Center
Columbus, Ohio
University of Pennsylvania
Philadelphia, Pennsylvania
Vanderbilt University Medical Center
Nashville, Tennessee
Baylor Health Care System
Dallas, Texas
University of Washington
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.